Home > Oncology > SABCS 2021 > Miscellaneous > Olaparib is well tolerated as an additional treatment

Olaparib is well tolerated as an additional treatment

Presented By
Dr Patricia Ganz, UCLA School of Medicine, CA, USA

Notice: Undefined index: new_doi_fields in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 138

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 138

Notice: Undefined index: new_doi_fields in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 174

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 174

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 175
Conference
SABCS 2021
Trial
Phase 3, OlympiA
Adjuvant treatment with the PARP-inhibitor olaparib showed beneficial effects for patients with BRCA1/2 mutations and high-risk, HER2-negative, early-stage, primary breast cancer. In addition, patient-reported outcomes (PROs) demonstrated no negative impact on the quality of life. OlympiA (NCT02032823) is a randomised, double-blind, placebo-controlled, phase 3 trial evaluating the efficacy and safety of the PARP-inhibitor olaparib in patients with germline BRCA1/2 mutations and high-risk, HER2-negative, early-stage, primary breast cancer who have completed definitive local treatment and neoadjuvant or adjuvant chemotherapy. A recently published interim analysis at a median follow-up of 2.5 years showed the 3-year invasive disease–free survival to be 85.9% in the olaparib group and 77.1% in the placebo g...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on